mygooi CEO Paul N. Greenwood thanks Iowans for their support in finding treatment successful for patients with the most common form of the disease.
The results of two 24-week studies held at 200 sites in North America, Europe and Australia, were announced Tuesday, June 24th (http://investors.vrtx.com/releasedetail.cfm?ReleaseID=856185) by Vertex Pharmaceuticals Inc., which developed the drugs and protocol with the support of the Cystic Fibrosis Foundation.
“This is monumental news,” said Greenwood, “the most exciting in CF history. I have to thank the people of Iowa, who contributed millions of dollars to this cause in the 10 years I’ve been volunteering with our chapter. This is a terrible disease and, while there’s still a lot of work to be done, this is a massive step forward.”
Vertex and CFF said the studies showed significant improvements for people with two copies of the F508del mutation, about half of all CF cases. Vertex is looking for possible FDA approval of the treatment in 2015. Robert J. Beall, Ph.D., national president and CEO of CFF, said the studies “validate that we are on the right road to getting new and effective treatments into the hands of people who so desperately need them.”
More than 1,100 people ages 12 and older participated in the studies. Those given the treatment showed significant and consistent improvement in lung function and other important health measures for CF, including weight gain and a reduction in the rate of pulmonary exacerbations and related hospitalizations and IV antibiotic use.
Check out the Cystic Fibrosis Foundation at http://www.cff.org.